Medical Information Only. Consult your healthcare provider before considering clinical trial enrollment.

ClinicalTrials.gov enrollment closed early-phase tilt small index

Leukemia, Mast-Cell: early-phase trial registry

A small indexed set (1 trial) with no open enrollment listed right now.

Corpus placement: #11,370 of 28,707 conditions by registered trial count.

1 US clinical trials · none currently recruiting · #11,370 of 28,707 conditions by registered trial count

Leukemia, Mast-Cell: 1 US clinical trial tracked, none currently recruiting.

Leukemia, Mast-Cell is the subject of 1 registered US clinical trials on ClinicalTrials.gov, none currently recruiting. 0 are in Phase 3-4 (later-stage) and 1 in Phase 1-2 (earlier-stage). The most active sponsor is Stanford University, running 1 of these trials.

Enrollment posture brief

Registry condition leukemia-mast-cell

OPEN 0 | RECR 0% | LATE 0 | EARLY 1 | RANK #11370 | SPON 1

Nearest open-share peer: Accelerated Phase Chronic Myelogenous Leukemia (0% recruiting · 12 trials)

Ablation80%ACL Reconstruction80%Abuse, Drug60%Acceptability60%Leukemia, Mast-Cell (this)0%
Open-enrollment share among volume-matched conditions near Leukemia, Mast-Cell

Leukemia, Mast-Cell has no open enrollment in this registry pull (1 archived studies). Peers show how other volume-matched labels compare on open share. How peer matching works →

Key findings

What ClinicalTrials.gov does not surface for Leukemia, Mast-Cell on its own pages , computed from the registry mirror as of 2026-08-08. Each line carries its own denominator so it can be quoted as it stands.

  1. Leukemia, Mast-Cell is recruiting below its size-band peers.

    0 of 1 indexed trials (0%) are open to enrollment, against a 46.5% average across 27,806 conditions with fewer than 20 trials. The peer set uses the same ClinicalTrials.gov-derived counts as this page.

Phase 21

Phase Distribution

PhaseTrial count
Phase 2 1

Top Sponsors

Named interventions

Most-linked intervention names on Leukemia, Mast-Cell records (sponsor-reported on ClinicalTrials.gov). Counts are trial links, not unique products.

Anti-thymoglobulin, rabbit (ATG, rabbit ATG) Drug
1 trials
Total lymphoid irradiation Procedure
1 trials
Mycophenylate mofetil Drug
1 trials
Cyclosporine Drug
1 trials
Rituximab Drug
1 trials

US sites by state

Facility locations filed on Leukemia, Mast-Cell trials. A trial with sites in several states counts in each.

California 1 trials

Source: ClinicalTrials.gov, National Library of Medicine. Data is informational only.

What to do with this Leukemia, Mast-Cell page

1 registered trials, 0 currently recruiting, is a starting point for a conversation, not a diagnosis or a recommendation.

  • No Leukemia, Mast-Cell trials are currently recruiting in this registry; that can change as new trials post, or check the broader research index. Browse research indexes
  • Stanford University sponsors the most Leukemia, Mast-Cell trials on record, review their full trial history before evaluating a specific study. See Stanford University's trials
  • Bring the specific trial ID (NCT number) to your own doctor before enrolling, this page is a directory, not medical guidance. Read the trial-finding guide

Trial and recruiting counts reflect ClinicalTrials.gov registry status as of the data vintage above; individual trial eligibility and enrollment status can change.

Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This Leukemia, Mast-Cell condition card totals 1 registered trials; most-linked intervention Anti-thymoglobulin, rabbit (ATG, rabbit ATG); top US site state California. See our editorial standards & corrections policy, the methodology behind these numbers, the data changelog, or report a data error.